{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.33","value":"0.54"},{"groupId":"OG001","spread":"26.48","value":"7.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.08","value":"4.84"},{"groupId":"OG001","spread":"24.76","value":"9.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"158"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.44","value":"6.60"},{"groupId":"OG001","spread":"26.62","value":"8.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"152"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.64","value":"7.67"},{"groupId":"OG001","spread":"26.98","value":"7.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"150"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.81","value":"8.42"},{"groupId":"OG001","spread":"25.70","value":"9.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.93","value":"8.17"},{"groupId":"OG001","spread":"24.74","value":"8.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"143"}],"units":"Participants"}],"title":"Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.51","value":"7.41"},{"groupId":"OG001","spread":"24.50","value":"10.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"136"}],"units":"Participants"}],"title":"Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.10","value":"7.26"},{"groupId":"OG001","spread":"28.26","value":"8.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"131"}],"units":"Participants"}],"title":"Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.79","value":"8.56"},{"groupId":"OG001","spread":"24.82","value":"11.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"Cycle 10 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.69","value":"8.02"},{"groupId":"OG001","spread":"24.23","value":"12.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"122"}],"units":"Participants"}],"title":"Cycle 11 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.51","value":"6.84"},{"groupId":"OG001","spread":"22.90","value":"11.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.04","value":"11.11"},{"groupId":"OG001","spread":"23.18","value":"10.72"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"title":"Cycle 13 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.86","value":"8.85"},{"groupId":"OG001","spread":"23.29","value":"11.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"title":"Cycle 14 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.16","value":"9.55"},{"groupId":"OG001","spread":"22.27","value":"12.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"title":"Cycle 15 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.51","value":"12.42"},{"groupId":"OG001","spread":"25.20","value":"11.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"title":"Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.64","value":"12.29"},{"groupId":"OG001","spread":"25.29","value":"10.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"101"}],"units":"Participants"}],"title":"Cycle 17 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.41","value":"11.36"},{"groupId":"OG001","spread":"23.25","value":"7.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"title":"Cycle 18 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.96","value":"9.21"},{"groupId":"OG001","spread":"25.50","value":"8.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"90"}],"units":"Participants"}],"title":"Cycle 19 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.67","value":"10.13"},{"groupId":"OG001","spread":"25.34","value":"9.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"88"}],"units":"Participants"}],"title":"Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.41","value":"10.32"},{"groupId":"OG001","spread":"26.15","value":"10.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"title":"Cycle 21 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.28","value":"8.77"},{"groupId":"OG001","spread":"22.35","value":"12.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"title":"Cycle 22 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.81","value":"9.63"},{"groupId":"OG001","spread":"20.48","value":"12.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Cycle 23 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.50","value":"1.23"},{"groupId":"OG001","spread":"18.70","value":"16.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Cycle 24 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.34","value":"-4.44"},{"groupId":"OG001","spread":"16.67","value":"15.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Cycle 25 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.86","value":"-3.95"},{"groupId":"OG001","spread":"31.45","value":"-3.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"57"}],"units":"Participants"}],"title":"End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. It consists of three questions and the scores are based on the 4-point Likert scale ranging from \"Not at all\" to \"Very much\". Future Perspective score is calculated as (1 - (\\[{Q48+Q49+Q50}/3\\] -1)/3)\\*100. Scores are averaged and transformed to scale ranging from 0 to 100. A higher score represents a better quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received carfilzomib 20 mg/m\\^2, IV infusion on Days 1, and 2 in Cycle 1, and then escalated to 56 mg/m\\^2 on Days 8, 9, 15 and 16 of Cycle 1 and then on Days 1, 2, 8, 9, 15 and 16 of each subsequent 28-day treatment cycle along with dexamethasone 20 mg, PO or IV on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day treatment cycle until disease progression or unacceptable adverse event or participant's decision to discontinue the study treatment or any other reason, whichever comes first (maximum exposure: 114 weeks).","id":"OG000","title":"Carfilzomib + Dexamethasone (Kd)"},{"description":"Participants received isatuximab 10 mg/kg, IV infusion on Days 1, 8, 15 and 22 in Cycle 1, and then on Days 1 and Day 15 of each 28-day treatment cycle plus carfilzomib 20 mg/m\\^2, IV on Days 1, and 2 in Cycle 1, and then escalated to 56 mg/m\\^2 on Days 8, 9, 15 and 16 of Cycle 1 and then on Days 1, 2, 8, 9, 15 and 16 of each subsequent 28-day treatment cycle and dexamethasone 20 mg, PO or IV on Day 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day treatment cycle until disease progression or unacceptable adverse event or participant's decision to discontinue the study treatment or any other reason, whichever comes first (maximum exposure: 111 weeks).","id":"OG001","title":"Isatuximab + Carfilzomib + Dexamethasone (IKd)"}],"paramType":"MEAN","populationDescription":"Analysis was performed on ITT population. Here, 'Number analyzed' signifies participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)","title":"HRQL: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 20 Items (EORTC QLQ-MY20): Future Perspective at Specified Timepoints: Primary Analysis","type":"SECONDARY","unitOfMeasure":"score on a scale"}